These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 1443357

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.
    Canawati HN.
    Diagn Microbiol Infect Dis; 1989; 12(1):33-7. PubMed ID: 2714070
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
    Aldridge KE.
    Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synergistic activity of cefotaxime and desacetylcefotaxime against the Bacteroides fragilis group.
    Cornick NA, Gorbach SL.
    Diagn Microbiol Infect Dis; 1988 Jun; 10(2):81-4. PubMed ID: 3224498
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of cefotaxime alone and in combination with desacetylcefotaxime against strains of Staphylococcus aureus that produce variants of staphylococcal beta-lactamase.
    Stratton CW, Kernodle DS, Eades SC, Weeks LS.
    Diagn Microbiol Infect Dis; 1989 Jun; 12(1):57-65. PubMed ID: 2785444
    [Abstract] [Full Text] [Related]

  • 10. In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.
    Aldridge KE, Sanders CV, Marier RL.
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):47S-53S. PubMed ID: 6086218
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks.
    Stevens DL, Bergstrom R, Gibbons A.
    Diagn Microbiol Infect Dis; 1989 Jun; 12(1):73-80. PubMed ID: 2653715
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Activity of cefotaxime/desacetylcefotaxime with two aminoglycosides against gram-negative pathogens: an example of interactive synergy.
    Jenkins SG.
    Diagn Microbiol Infect Dis; 1989 Jun; 12(1):51-5. PubMed ID: 2714073
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.
    Devlin HR, Boskovski L.
    Drugs; 1988 Jun; 35 Suppl 2():45-50. PubMed ID: 3396488
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro comparison of the activity of cefotaxime and desacetylated cefotaxime and of their combination.
    Nanetti A, La Placa M.
    J Chemother; 1990 Jun; 2(3):159-63. PubMed ID: 2380765
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of disk susceptibility testing of cefotaxime/desacetylcefotaxime.
    Fuchs PC, Jones RN, Barry AL.
    Diagn Microbiol Infect Dis; 1989 Jun; 12(1):81-5. PubMed ID: 2714075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.